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Abstract
Myocilin gene is directly linked to the most 
common form of glaucoma. The gene product is 
secreted into aqueous humor and is thought to be 
involved in the regulation of intraocular pressure. 
Most of the mutant myocilin proteins accumulate 
in cultured cells and are not secreted. In this 
study, through staining experiments of various 
cell lines, we demonstrated that secreted myocilin 
could bind to a particular cell surface to exert its 
function. Myocilin secreted by COS-1 cells was 
able to bind specifically to the surface of NIH3T3 
cells. The binding of myocilin was dependent on 
the cell density. These results suggest that 
myocilin recognizes a specific cell and exerts its 
effect upon binding to the cell surface. 
Introduction
Glaucoma is a progressive blinding disease that 
is characterized by the gradual loss of vision due 
to optic neuropathy and retinal ganglion cell 
death, and is the second largest cause of bilateral 
blindness in the world. It is speculated that there 
are an estimated 70 million glaucoma patients 
worldwide and thus, it is one of the most 
prevalent vision disorders that require immediate 
attention (Quigley, 1996). The relationship of the 
mechanism of onset with various factors, such as 
a mutation in the gene and the environment, has 
been extensively examined. However, little is 
known about the underlying pathological 
mechanism. 
Myocilin was originally identified as trabecular 
meshwork inducible glucocorticoid response gene 
(TIGR) (Polansky et al., 1997). Mutations in the 
myocilin gene were found in 3-4% of patients 
with primary open angle glaucoma (POAG), the 
most common form of glaucoma (Stone et al., 
1997), and in a subset of families with autosomal 
dominant juvenile-onset open angle glaucoma 
(OAG) and adult-onset OAG (Fingert et al., 1999, 
2002). It has been shown that the myocilin 
knockout mouse and the transgenic mouse 
expressing a high level of wild-type myocilin in 
the angle tissue do not exhibit the glaucoma 
phenotype (Kim et al., 2001; Gould et al., 2004). 
Therefore, it is surmised that the change in 
myocilin expression level is not responsible for 
the onset of glaucoma. Senatorov et al. (2006) 
reported that the OAG-like phenotype was 
induced in mouse expressing a specific mutant 
myocilin. The above findings support the idea 
that specific mutant myocilins are responsible for 
the onset of various glaucoma. 
Myocilin is ubiquitously distributed in various 
locations, including non-ocular tissues and 
organs, and strongly expressed in various 
components of the eye, namely, aqueous humor, 
sclera, iris, cornea, lens, ciliary body, optic nerve, 
retina, and trabecular meshwork (Kubota et al., 
1997; Polansky et al., 1997; Nguyen et al., 1998; 
Karali et al., 2000; Noda et al., 2000; Rao et al., 
2000; Clark et al., 2001; Fautsch and Johnson, 
2001; Ricard et al., 2001; Russell et al., 2001; 
Tamm, 2002). Myocilin is a glycoprotein 
composed of 504 amino acids and has a molecular 
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weight of 55-57 kDa. Myocilin has its own signal 
peptide sequence followed by a leucine zipper at 
the amino terminal region and an olfactomedin 
domain at the carboxyl terminal region (Kubota 
et al., 1997; Polansky et al., 1997; Nguyen et al., 
1998; Tamm, 2002). Approximately 70 myocilin 
mutations have been identified in human 
glaucoma patients, and a majority of these 
glaucoma-associated mutations are localized in 
the olfactomedin domain (Fingert et al., 2002; 
Tamm, 2002; Gong et al., 2004). It is thought that 
most mutant myocilin proteins are misfolded, 
insoluble in detergent, and retained in the 
endoplasmic reticulum. Thus, the protein is 
poorly soluble in aqueous humor or culture 
medium (Jacobson et al., 2001; Sohn et al., 2002; 
Joe et al., 2003; Gobeil et al., 2004; Liu and 
Vollrath, 2004; Vollrath and Liu, 2006). Based on 
these results, some researchers predict that 
secreted myocilin may regulate intraocular 
pressure (IOP) and mutant myocilin proteins may 
impair eye function, leading to the onset of 
diseases. In fact, some neuronal conformational 
diseases are thought to be dominant 
neurodegenerative disorders in which the toxic 
effects of misfolded proteins lead directly to 
neuronal death, causing Parkinson’s disease and 
neuroserpin-associated dementia (Davis et al., 
2002; Lee and Trojanowski, 2006). 
However, details of the molecular mechanisms 
underlying the pathogenesis of glaucoma caused 
by such mutations remain unclear. In this study, 
to gain an insight into the physiological functions 
of myocilin, we tried to determine the specific 
target of secreted-myocilin binding cell(s) using 
various cultured cell lines. 
Materials and Methods
Cell lines and cell culture 
COS-1, A549, and NIH3T3 cells were 
maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) wi th  h igh  g lucose 
supplemented with 10% fetal bovine serum. 
RGC-5 cells were grown in similar conditions 
except that DMEM with low glucose was used. 
HEK293 cells were maintained in minimal 
essential medium (MEM) supplemented with 2 
mM L-glutamine, non-essential amino acids, and 
10% fetal bovine serum. All cells were cultured 
under 5% CO2 at 37˚C.
Plasmid construction
Wild-type full-length human myocilin cDNA 
was cloned into pcDNA3.1(-) (Invitrogen) as 
described previously (Izumi et al., 2003). This 
vector was digested with HindIII and XhoI, and 
the myocilin cDNA fragment was inserted into 
the HindIII-XhoI site of the mammalian 
expression vector pcDNA4/V5-HisA (Invitrogen) 
that produces C-terminus histidine-tagged fusion 
protein. 
To construct the mutant myocilin (N57Q) 
expression vector, we inserted a point mutation 
using a QuickChange XL Site-Directed 
Mutagenesis Kit (Stratagene) with two 
oligonucleotides (5'-GTGTGGCCAGTCCCCAA
GAATCCAGCTGCCC-3’ and 5’-GGGCAGCTG
G AT T C T T G G G G A C T G G C C A C A C - 3 ’ ) 
according to the manufacturer’s protocol. 
Transfection and addition of myocilin
To perform indirect immunofluorescence 
experiments, COS-1 cells were grown to 80-90% 
confluence in a 24-well plate (Becton Dickinson) 
and cultured for 12-16 hours prior to transfection. 
For the transfection experiment, cells were 
washed with PBS(+) (phosphate-buffered saline 
containing 0.9 mM CaCl2 and 0.5 mM MgCl2) 
and replaced with corresponding culture medium. 
Cells were transfected with pcDNA4/V5-HisA 
(negative control) or myocilin expression vector 
using Lipofectamine 2000 (Invitrogen) according 
to the manufacturer’s protocol with a ratio of 2 
μL of transfection reagent per 0.8 μg of plasmid. 
After transfection for six hours, cells were 
washed with PBS(+) three times to remove 
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transfection reagents and plasmids, and were 
replaced with 0.4 mL of fresh medium. After 
culture of forty-eight hours, the medium was 
collected and debris was removed by 
centrifugation. The supernatant was added to the 
pre-cultured cells as described below. In the 
experiments of Figure 1B, non-diluted myocilin-
containing medium (1); the medium diluted 1:3 
or 1:9 with control plasmid expression medium; 
and control medium (0) were added to NIH3T3 
cells. 
To the culture at 50-60% confluence, COS-1, 
A549, HEK293, and NIH3T3 cells were seeded 
at a density of 7.5 x 103 cells/cm2, and RGC-5 
cells were seeded at a density of 1.5 x 104 cells/
cm2 in an 8-well chamber (Nalge-Nunc). In the 
experiments presented in Figure 3, to test the 
relationship between cell density and binding 
capability of myocilin, NIH3T3 cells were seeded 
at a density of 1.5 x 103 cells/cm2 (10-20% 
confluence) or 7.5 x 103 cells/cm2 (50-60% 
confluence) in an 8-well chamber. The cells were 
cultured for 12-16 hours and myocilin-containing 
medium was added.  
Anti-human myocilin antibody
Synthesized peptide (TRDTARAVPPGSREVST; 
corresponding to amino acid positions 188 to 
204) was injected into rabbit, and anti-human 
myocilin antibody was affinity purified using a 
peptide-conjugated column. This antibody was 
diluted to 1:10000 for Western blot analysis and 
to 1:750 for indirect immunofluorescence 
experiment. 
Western blot analysis 
The medium was combined with Laemmli 
sample buffer (Laemmli 1970) and incubated at 
100˚C for 5 min. Proteins were separated by 
SDS-PAGE under reducing conditions using a 
Mini-PROTEAN 3 Electrophoresis System (Bio-
Rad), and transferred electrophoretically to PVDF 
membranes. Membranes were blocked with milk 
diluent/blocking solution (KPL) and incubated 
with anti-human myocilin antibody. Then, the 
membranes were washed with TBS-T (Tris-
buffered saline containing 0.05% Tween20), 
incubated with horseradish-peroxidase-
conjugated anti-rabbit IgG, and washed with 
TBS-T. Protein-antibody complexes were reacted 
with SuperSignal West Femto Maximum 
Sensitivity Substrate (Pierce) and detected with 
Lumi-Imager F1 (Roche). 
Indirect immunofluorescence experiment
Cells were rinsed with PBS(+) three times and 
fixed with 4% paraformaldehyde solution at room 
temperature for 20 min. Cells were washed with 
PBS three times and permeabilized by treatment 
with 0.1% Triton X-100 solution for 10 min. 
Cells were washed with PBS three times and 
blocked with 5% goat serum in PBS at room 
temperature for 1 hour. Cells were washed with 
PBS three times and incubated with anti-human 
myocilin antibody diluted with 1% goat serum in 
PBS at 4˚C overnight. Cells were washed with 
PBS three times and incubated with Alexa488-
conjugated anti-rabbit IgG (Invitrogen) and DAPI 
(4’,6-diamidino-2-phenylindole, dihydrochloride) 
(Sigma-Aldrich) solution at room temperature for 
1 hour. Cells were washed with PBS three times 
and observed under a confocal microscope 
(Radiance 2100, Bio-Rad). To confirm that the 
interaction between myocilin and NIH3T3 cells 
occurs only on the cell surface, the results of 
which are presented in Figure 5, we carried out 
the above staining experiment without Triton 
X-100 treatment. 
Results
Myocilin specifically binds to NIH3T3 cells
The extent of degradation of secreted myocilin 
depends on the cell species (Aroca-Aguilar et al., 
2005). As most of the secreted myocilin was not 
degraded when COS-1 cells were used for 
expression, we selected this cell line for the 
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following experiments.
In order to verify the possibility that myocilin 
exerts its function upon binding to the cell 
surface, we examined whether myocilin is able to 
bind to various cells. Histidine-tagged 
recombinant myocilin was expressed in COS-1 
cells and the culture medium containing secreted 
myocilin was collected. This medium was added 
to 50-60% confluent RGC-5, COS-1, A549, and 
HEK293 cells, and the cells were cultured for 96 
hours.  Cells  were f ixed and indirect 
immunofluorescence experiments were carried 
out with anti-human myocilin antibody. The 
results indicated that myocilin could not bind to 
these cells (Figure 1A). In contrast, myocilin 
bound specifically to NIH3T3 cells when non-
diluted (1) or diluted myocilin-containing 
medium (1:3 or 1:9) was added (Figure 1B). 
Myocilin appeared as a dot-like pattern and did 
not localize at a definite site. We proposed two 
reasons why myocilin bound not to the other cells 
but to NIH3T3. One was that the amount of 
myocilin added was different in each medium 
because myocilin expression depends on the 
composition of the medium (Fautsch et al., 2005). 
The other was that myocilin was degraded during 
incubation. 
To exclude the above possibilities, Western blot 
experiments were conducted to estimate myocilin 
expression. Myocilin expression was not 
significantly different among the media (Figure 
2A). Signals derived from NIH3T3 cells were 
detected when myocilin-containing medium was 
diluted 1:3 or 1:9 with control plasmid expression 
medium. Under these experimental conditions, it 
was clear that myocilin expression in the diluted 
medium was apparently lower than that in the 
other media (Figure 2A). Also, myocilin was not 
completely degraded even after incubation for 96 
hours (Figure 2B). Therefore, we concluded that 
undegraded wild-type myocilin could specifically 
bind to the surface of NIH3T3 cells.
Binding of myocilin to NIH3T3 cells depends on 
cell density
To analyze the binding pattern of myocilin to 
NIH3T3 cells in detail, we examined the 
relationship between the binding ability of 
myocilin and the density of NIH3T3 cells. After 
incubation for 48 hours, we could not detect the 
interaction of myocilin with NIH3T3 cells when 
the cell density was 1.5 x 103/cm2 (Figure 3A). 
On the other hand, the interaction was observed 
when the cell density was 7.5 x 103/cm2 (Figure 
3B). Some detectable large dot-like signals could 
not be explained at present. After incubation for 
96 hours, myocilin was able to bind to NIH3T3 
cells regardless of the cell density.
Glycosylation of myocilin does not affect its 
binding ability to NIH3T3 cells
It is known that secreted myocilin is 
glycosylated and post-translational modification 
is involved in such molecular functions as cell-
cell or receptor-ligand binding (Ohtsubo and 
Marth, 2004). Therefore, to investigate whether 
or not glycosylation is required for myocilin to 
exert its binding ability, we substituted the 
glycosylated asparagine residue at position 57 
with glutamine (N57Q) and examined the binding 
ability of this mutant myocilin to NIH3T3 cells. 
The result indicated that the mutant myocilin was 
secreted into the medium and its binding ability 
was comparable to that of non-mutant myocilin 
(Figures 1B and 4).
Myocilin binds to cell surface
To confirm that the added myocilin is able to 
bind to the NIH3T3 cell surface, we performed 
indirect immunofluorescence experiments without 
Triton X-100 treatment (without permeabilization 
treatment). The result indicated that myocilin 
bound to NIH3T3 cells and the binding pattern 
was similar to that obtained with Triton X-100 
treatment (Figures 1B and 5). 
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Discussion
A number of groups have examined the 
localization of myocilin and demonstrated that 
myocilin is distributed in both intra- and 
extracellular sites. For example, myocilin is 
localized in the mitochondria, Golgi complex, 
and endoplasmic reticulum of cells (Wentz-
Hunter et al., 2003; Sakai et al., 2007). At the 
extracellular sites, myocilin is present at the site 
of type IV collagen, fibronectin, and laminin 
(Tawara et al., 2000; Lindsey et al., 2001; Filla et 
al., 2002; Ueda et al., 2002). In this study, we 
demonstrated by means of a staining experiment 
that recombinant myocilin secreted into the 
culture medium specifically bound to the surface 
of NIH3T3 cells, and added myocilin was not 
degraded during incubation under our 
experimental conditions (Figures 1 and 2). 
Therefore, we concluded that undegraded intact 
myocilin is able to bind to NIH3T3 cells. To our 
knowledge, this is the first finding that the binding 
ability of myocilin depends on the cell species. 
Myocilin binding to NIH3T3 cells was 
dependent on cell density. Myocilin bound to 
NIH3T3 cells when NIH3T3 cell density was 
high. In contrast, myocilin did not bind to low-
density pre-seeded cells (Figure 3). These results 
lead us to speculate that myocilin could directly 
bind to molecules that are involved in cell-cell 
adhesion (such as tight junction and/or adherens 
junction). However, the binding sites are not 
limited to the cell-cell adhesion sites. Therefore, 
we need further analysis to determine myocilin 
binding sites.
The physiological meaning of the interaction 
between myocilin and NIH3T3 cells remains 
unclear. From our examinations, we noted that 
there was neither drastic morphological change 
nor cell death following the addition of myocilin. 
However, from the fact that myocilin is 
ubiquitously expressed, it is plausible that 
myocilin acts on a cell that has characteristics 
similar to NIH3T3 cells, and regulates the flow 
rate of aqueous humor within the eye. Indeed, it 
has been reported that extracellular myocilin 
impairs focal adhesion formation, decreases cell 
motility, and increases outflow resistance 
(Caballero et al., 2000; Fautsch et al., 2000, 2006; 
Wentz-Hunter et al., 2004; Peters et al., 2005). 
Also, several data suggest that certain 
olfactomedin-domain-containing proteins could 
interact with proteins localized at the cell surface. 
For example, gliomedin, a glial ligand for 
neurofascin and NrCAM, interacts with these 
proteins at the nodes of Ranvier (Eshed et al., 
2005, 2006). hCG1 may interact with cell surface 
lectins and cadherins (Liu et al., 2006). Amassin 
mediates the massive Ca2+-dependent intracellular 
adhesion of sea urchin coelomocytes by binding 
to a cell surface protein (Hillier and Vacquier, 
2003). We are currently trying to identify 
myoci l in-associated proteins  by mass 
spectrometry to further understand the function of 
myocilin.
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Figure 1. Myocilin binds specifically to NIH3T3 cells
(A) Myocilin-expression plasmid was transfected into COS-1 cells and medium containing 
secreted myocilin was added to pre-seeded RGC-5, COS-1, A549, and HEK293 cells. (B) 
Myocilin-containing medium was diluted 1:3 or 1:9 with control plasmid pcDNA4/V5-HisA 
expression medium. We added non-diluted myocilin-containing medium (1), diluted 
medium (1:3 and 1:9), and pcDNA4/V5-HisA expression medium only (0) into pre-seeded 
NIH3T3 cells. Scale bar, 20 μm.
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Figure 2. The amount of myocilin added is not responsible for the specific interaction 
(A) Myocilin was expressed in different culture media. To estimate the amount of myocilin 
added, non-diluted or diluted myocilin-containing medium was mixed with Laemmli buffer, and 
Western blot experiment with anti-human myocilin antibody was carried out. Non-diluted 
myocilin-containing culture medium for HEK293 (lane 1), RGC-5 (lane 2), and NIH3T3, COS-
1, and A549 (lane 3). Culture medium for NIH3T3, COS-1, and A549 was diluted 1:3 (lane 4) 
and 1:9 (lane 5). (B) To confirm that myocilin degradation did not occur during incubation, we 
examined myocilin expression by Western blot experiment using culture medium incubated 
for 96 hours. Non-diluted culture media were as follows: COS-1 (lane 1), HEK293 (lane 2), 
RGC-5 (lane 3), A549 (lane 4), and NIH3T3 (lane 5). Culture medium for NIH3T3 was diluted 
1:3 (lane 6) and 1:9 (lane 7).
49
The Niigata Journal of Health and Welfare Vol. 9, No. 1
Figure 3. Binding of myocilin to NIH3T3 cells is dependent on cell density
NIH3T3 cells were pre-seeded at a density of 1.5 x 103/cm2 or 7.5 x 103/cm2. Myocilin-containing medium 
was added and indirect immunofluorescence experiment was carried out after incubation for 48 hours (A) 
or 96 hours (B). Scale bar, 20 μm.
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Figure 4. Glycosylation of myocilin does not affect binding ability 
Glycosylation site of asparagine residue at position 57 was substituted with glutamine 
residue, and this mutant myocilin-expression plasmid was transfected into COS-1 
cells. This mutant myocilin-containing medium was added to pre-seeded NIH3T3 cells 
and indirect immunofluorescence experiment was carried out after incubation for 96 
hours. Scale bar, 20 μm.
Figure 5. Myocilin binds to the surface of NIH3T3 cells
Myocilin-containing medium was added to pre-seeded NIH3T3 cells and indirect 
immunofluorescence experiment was carried out without Triton X-100 treatment after 
incubation for 96 hours. Scale bar, 20 μm.
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